JMP Securities Reaffirms Market Outperform Rating for Savara (NASDAQ:SVRA)

JMP Securities restated their market outperform rating on shares of Savara (NASDAQ:SVRA) in a research report report published on Tuesday morning, Benzinga reports. The brokerage currently has a $9.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Oppenheimer upped their price objective on shares of Savara from $11.00 to $15.00 and gave the stock an outperform rating in a report on Wednesday, June 26th. Guggenheim upped their price target on Savara from $8.00 to $10.00 and gave the stock a buy rating in a research note on Thursday, June 27th. Finally, HC Wainwright reissued a buy rating and issued a $10.00 price objective on shares of Savara in a research note on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $11.17.

Savara Stock Up 0.3 %

Shares of Savara stock opened at $3.82 on Tuesday. The firm has a market cap of $527.88 million, a price-to-earnings ratio of -10.32 and a beta of 0.97. The stock has a 50-day simple moving average of $4.28 and a 200-day simple moving average of $4.44. Savara has a 52-week low of $3.12 and a 52-week high of $5.70. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31.

Savara (NASDAQ:SVRA) last posted its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). On average, equities research analysts expect that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Hedge funds and other institutional investors have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co acquired a new position in shares of Savara during the 1st quarter worth about $35,000. Choreo LLC bought a new position in Savara in the 2nd quarter worth approximately $59,000. DRW Securities LLC acquired a new position in shares of Savara during the second quarter worth approximately $62,000. Principal Financial Group Inc. boosted its position in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the period. Finally, ProShare Advisors LLC boosted its position in shares of Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after acquiring an additional 2,114 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.